PMC:7386875 / 16888-18196 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T104","span":{"begin":566,"end":574},"obj":"Body_part"},{"id":"T105","span":{"begin":575,"end":584},"obj":"Body_part"},{"id":"T106","span":{"begin":742,"end":750},"obj":"Body_part"},{"id":"T107","span":{"begin":773,"end":781},"obj":"Body_part"},{"id":"T108","span":{"begin":843,"end":864},"obj":"Body_part"},{"id":"T109","span":{"begin":894,"end":899},"obj":"Body_part"},{"id":"T110","span":{"begin":1182,"end":1186},"obj":"Body_part"}],"attributes":[{"id":"A104","pred":"fma_id","subj":"T104","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A105","pred":"fma_id","subj":"T105","obj":"http://purl.org/sig/ont/fma/fma63194"},{"id":"A106","pred":"fma_id","subj":"T106","obj":"http://purl.org/sig/ont/fma/fma264783"},{"id":"A107","pred":"fma_id","subj":"T107","obj":"http://purl.org/sig/ont/fma/fma62851"},{"id":"A108","pred":"fma_id","subj":"T108","obj":"http://purl.org/sig/ont/fma/fma73750"},{"id":"A109","pred":"fma_id","subj":"T109","obj":"http://purl.org/sig/ont/fma/fma68877"},{"id":"A110","pred":"fma_id","subj":"T110","obj":"http://purl.org/sig/ont/fma/fma256135"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T18","span":{"begin":575,"end":584},"obj":"Body_part"},{"id":"T19","span":{"begin":853,"end":864},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0001982"},{"id":"A19","pred":"uberon_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/UBERON_0002049"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T165","span":{"begin":77,"end":85},"obj":"Disease"},{"id":"T166","span":{"begin":105,"end":115},"obj":"Disease"},{"id":"T167","span":{"begin":141,"end":151},"obj":"Disease"},{"id":"T168","span":{"begin":223,"end":227},"obj":"Disease"},{"id":"T169","span":{"begin":277,"end":281},"obj":"Disease"},{"id":"T170","span":{"begin":333,"end":341},"obj":"Disease"},{"id":"T171","span":{"begin":417,"end":425},"obj":"Disease"},{"id":"T172","span":{"begin":428,"end":437},"obj":"Disease"},{"id":"T173","span":{"begin":473,"end":481},"obj":"Disease"},{"id":"T174","span":{"begin":493,"end":512},"obj":"Disease"},{"id":"T175","span":{"begin":631,"end":640},"obj":"Disease"},{"id":"T176","span":{"begin":767,"end":771},"obj":"Disease"},{"id":"T177","span":{"begin":1074,"end":1082},"obj":"Disease"},{"id":"T178","span":{"begin":1155,"end":1165},"obj":"Disease"},{"id":"T179","span":{"begin":1211,"end":1219},"obj":"Disease"},{"id":"T180","span":{"begin":1297,"end":1307},"obj":"Disease"}],"attributes":[{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A166","pred":"mondo_id","subj":"T166","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A168","pred":"mondo_id","subj":"T168","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A169","pred":"mondo_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A170","pred":"mondo_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A171","pred":"mondo_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A172","pred":"mondo_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A173","pred":"mondo_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A174","pred":"mondo_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/MONDO_0021113"},{"id":"A175","pred":"mondo_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A176","pred":"mondo_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A179","pred":"mondo_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A180","pred":"mondo_id","subj":"T180","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T129","span":{"begin":53,"end":54},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T130","span":{"begin":152,"end":155},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T131","span":{"begin":198,"end":199},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T132","span":{"begin":232,"end":235},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T133","span":{"begin":355,"end":357},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T134","span":{"begin":358,"end":360},"obj":"http://purl.obolibrary.org/obo/CLO_0053794"},{"id":"T135","span":{"begin":527,"end":530},"obj":"http://purl.obolibrary.org/obo/CLO_0001618"},{"id":"T136","span":{"begin":527,"end":530},"obj":"http://purl.obolibrary.org/obo/CLO_0001619"},{"id":"T137","span":{"begin":527,"end":530},"obj":"http://purl.obolibrary.org/obo/CLO_0001620"},{"id":"T138","span":{"begin":801,"end":802},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T139","span":{"begin":894,"end":899},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T140","span":{"begin":923,"end":925},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T141","span":{"begin":1041,"end":1042},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T142","span":{"begin":1225,"end":1226},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T35","span":{"begin":410,"end":437},"obj":"Phenotype"},{"id":"T36","span":{"begin":493,"end":512},"obj":"Phenotype"},{"id":"T37","span":{"begin":734,"end":757},"obj":"Phenotype"}],"attributes":[{"id":"A35","pred":"hp_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/HP_0033141"},{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0002878"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0033006"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T37","span":{"begin":1089,"end":1100},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-sentences","denotations":[{"id":"T73","span":{"begin":0,"end":116},"obj":"Sentence"},{"id":"T74","span":{"begin":117,"end":1101},"obj":"Sentence"},{"id":"T75","span":{"begin":1102,"end":1308},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"2_test","denotations":[{"id":"32586214-14660106-21597696","span":{"begin":355,"end":357},"obj":"14660106"},{"id":"32586214-12845623-21597696","span":{"begin":355,"end":357},"obj":"12845623"},{"id":"32586214-15272286-21597696","span":{"begin":355,"end":357},"obj":"15272286"},{"id":"32586214-14506633-21597696","span":{"begin":355,"end":357},"obj":"14506633"},{"id":"32586214-26486634-21597696","span":{"begin":355,"end":357},"obj":"26486634"},{"id":"32586214-6859225-21597696","span":{"begin":355,"end":357},"obj":"6859225"},{"id":"32586214-32294295-21597697","span":{"begin":920,"end":922},"obj":"32294295"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}

{"project":"LitCovid-PubTator","denotations":[{"id":"669","span":{"begin":308,"end":321},"obj":"Species"},{"id":"670","span":{"begin":333,"end":341},"obj":"Species"},{"id":"671","span":{"begin":346,"end":354},"obj":"Species"},{"id":"672","span":{"begin":459,"end":467},"obj":"Species"},{"id":"673","span":{"begin":617,"end":625},"obj":"Species"},{"id":"674","span":{"begin":1074,"end":1084},"obj":"Species"},{"id":"675","span":{"begin":1211,"end":1221},"obj":"Species"},{"id":"676","span":{"begin":631,"end":640},"obj":"Species"},{"id":"677","span":{"begin":77,"end":85},"obj":"Disease"},{"id":"678","span":{"begin":105,"end":115},"obj":"Disease"},{"id":"679","span":{"begin":117,"end":151},"obj":"Disease"},{"id":"680","span":{"begin":223,"end":227},"obj":"Disease"},{"id":"681","span":{"begin":277,"end":281},"obj":"Disease"},{"id":"682","span":{"begin":417,"end":437},"obj":"Disease"},{"id":"683","span":{"begin":473,"end":481},"obj":"Disease"},{"id":"684","span":{"begin":493,"end":512},"obj":"Disease"},{"id":"685","span":{"begin":742,"end":757},"obj":"Disease"},{"id":"686","span":{"begin":767,"end":771},"obj":"Disease"},{"id":"687","span":{"begin":789,"end":796},"obj":"Disease"},{"id":"688","span":{"begin":961,"end":971},"obj":"Disease"},{"id":"689","span":{"begin":1007,"end":1017},"obj":"Disease"},{"id":"690","span":{"begin":1155,"end":1165},"obj":"Disease"},{"id":"691","span":{"begin":1297,"end":1307},"obj":"Disease"}],"attributes":[{"id":"A669","pred":"tao:has_database_id","subj":"669","obj":"Tax:11118"},{"id":"A670","pred":"tao:has_database_id","subj":"670","obj":"Tax:694009"},{"id":"A671","pred":"tao:has_database_id","subj":"671","obj":"Tax:1335626"},{"id":"A672","pred":"tao:has_database_id","subj":"672","obj":"Tax:9606"},{"id":"A673","pred":"tao:has_database_id","subj":"673","obj":"Tax:9606"},{"id":"A674","pred":"tao:has_database_id","subj":"674","obj":"Tax:2697049"},{"id":"A675","pred":"tao:has_database_id","subj":"675","obj":"Tax:2697049"},{"id":"A676","pred":"tao:has_database_id","subj":"676","obj":"Tax:11309"},{"id":"A677","pred":"tao:has_database_id","subj":"677","obj":"MESH:C000657245"},{"id":"A678","pred":"tao:has_database_id","subj":"678","obj":"MESH:D013927"},{"id":"A679","pred":"tao:has_database_id","subj":"679","obj":"MESH:D013927"},{"id":"A680","pred":"tao:has_database_id","subj":"680","obj":"MESH:D012128"},{"id":"A681","pred":"tao:has_database_id","subj":"681","obj":"MESH:D012128"},{"id":"A682","pred":"tao:has_database_id","subj":"682","obj":"MESH:C000657245"},{"id":"A683","pred":"tao:has_database_id","subj":"683","obj":"MESH:C000657245"},{"id":"A684","pred":"tao:has_database_id","subj":"684","obj":"MESH:D012131"},{"id":"A685","pred":"tao:has_database_id","subj":"685","obj":"MESH:D055370"},{"id":"A686","pred":"tao:has_database_id","subj":"686","obj":"MESH:D012128"},{"id":"A687","pred":"tao:has_database_id","subj":"687","obj":"MESH:D013927"},{"id":"A688","pred":"tao:has_database_id","subj":"688","obj":"MESH:D013927"},{"id":"A689","pred":"tao:has_database_id","subj":"689","obj":"MESH:D013927"},{"id":"A690","pred":"tao:has_database_id","subj":"690","obj":"MESH:D013927"},{"id":"A691","pred":"tao:has_database_id","subj":"691","obj":"MESH:D013927"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In addition to macrovascular complications, there is a strong association of COVID-19 with microvascular thrombosis. Pulmonary microvascular thrombosis has been previously described in autopsies as a complication of severe ARDS and has subsequently been reported to complicate ARDS during outbreaks of other coronaviruses, including SARS-CoV and MERS-CoV.36–41 However, this feature appears more pronounced in severe SARS-CoV-2 infection, with histology from patients with COVID-19-associated respiratory failure demonstrating a 9-fold increase in the prevalence of alveolar-capillary microthrombi when compared with patients with influenza.42 In this regard, autopsy findings have shown that, in addition to the expected features of diffuse alveolar damage found in ARDS, platelet-fibrin thrombi are a common microscopic finding in the small pulmonary vasculature, occurring in 80% to 100% of lungs examined at autopsy.43–45 In combination with other reported thrombotic events, the emerging microvascular thrombotic complications indicate a strong interaction between the SARS-CoV-2 and coagulation. Below, we review the underlying known mechanisms for thrombosis and the growing body of work that implicates SARS-CoV-2 as a key player driving many molecular processes underpinning pathological thrombosis."}